Benign Bone Tumors and Tumor like Conditions

2022 ◽  
pp. 107-144
Author(s):  
Ronald L. Eisenberg
Keyword(s):  
Bone Tumors ◽  
Benign Bone Tumors

MALIGNANT AND BENIGN BONE TUMORS

2001 ◽  
Vol 39 (4) ◽  
pp. 673-699 ◽  
Author(s):  
Shannon L. Miller ◽  
Fredric A. Hoffer
Keyword(s):  
Bone Tumors ◽  
Benign Bone Tumors

scholarly journals Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 487-492 ◽  
Author(s):  
Daniel Kotrych ◽  
Szymon Korecki ◽  
Paweł Ziętek ◽  
Bartosz Kruk ◽  
Agnieszka Kruk ◽  
...  
Keyword(s):  
Bone Substitute ◽  
Bone Tumors ◽  
Bone Cyst ◽  
Bone Diseases ◽  
Long Term Results ◽  
Reconstructive Procedures ◽  
Benign Bone Tumors ◽  
Significant Clinical Improvement ◽  
Tumor Like Lesions

AbstractBackground: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.

Benign Bone Tumors

2010 ◽  
pp. 48-49
Author(s):  
Javad Parvizi ◽  
Gregory K. Kim
Keyword(s):  
Bone Tumors ◽  
Benign Bone Tumors

Common Benign Bone Tumors in Clinic

2014 ◽  
Vol 49 (6) ◽  
pp. 411
Author(s):  
Hwan Seong Cho ◽  
Yeong Kyoon Park ◽  
Joo Han Oh ◽  
Ilkyu Han ◽  
Han-Soo Kim
Keyword(s):  
Bone Tumors ◽  
Benign Bone Tumors

scholarly journals Complications of Computer Tomography Assisted Radiofrequency Ablation in the Treatment of Osteoid Osteoma

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Yunus Oc ◽  
Bekir Eray Kilinc ◽  
Sahin Cennet ◽  
Mehmet Metin Boyacioglu ◽  
Rodi Ertugrul ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Osteoid Osteoma ◽  
Bone Tumors ◽  
Skin Infection ◽  
Primary Bone Tumors ◽  
Benign Bone Tumors ◽  
Superficial Skin ◽  
Primary Bone ◽  
A Prospective Study

Background. Osteoid osteoma (OO) is one of the most commonly occurring benign bone tumors. It constitutes 10-12% of benign bone tumors and 2-3% of primary bone tumors. In radiofrequency ablation (RFA) treatment, the cells of the tumor are thermally inactivated by the help of electrodes shaped like needles. In our study, we aimed to show the major and minor complications in patients undergoing RFA and to show what should be done to prevent these complications. Methods. The study was carried out as a prospective study on the follow-up of 87 osteoid osteoma patients treated between 2015 and 2017. The youngest of the patients was 1 year old and the oldest was 42 years old. The RFA procedure lasted 10 min on average, excluding anesthesia and preparation. All lesions were ablated at 90 degrees for 7 minutes with the heat increased gradually. All patients were followed up for 1 day in the orthopedics clinic. Results. Complications were observed in 7 patients. The lesions with the most complications were observed to be in the tibia, second-degree burns were seen in 2 patients, and superficial skin infection was observed in 2 patients. In 1 patient, the probe tip was broken and remained within the bone. Intramuscular hematoma was detected in 1 lesion located in the proximal femur. A complaint of numbness in the fingers developed in a lesion located in the metacarpus. Conclusion. Preventive measures should be taken before the procedure in order to prevent minor complications, and, for major complications, close follow-up should be done after the procedure and patients should be kept away from heavy physical activities for the first 3 months.

Novel Unidirectional Porous β-Tricalcium Phosphate Used as a Bone Substitute after Excision of Benign Bone Tumors of the Hand: A Case Series

2018 ◽  
Vol 23 (03) ◽  
pp. 424-429 ◽  
Author(s):  
Akira Ikumi ◽  
Toru Funayama ◽  
Toshinori Tsukanishi ◽  
Hiroshi Noguchi ◽  
Masashi Yamazaki
Keyword(s):  
Bone Formation ◽  
Tricalcium Phosphate ◽  
Bone Substitute ◽  
Bone Tumors ◽  
Animal Studies ◽  
Case Series ◽  
Clinical Results ◽  
Benign Bone Tumors ◽  
Tumors Of The Hand ◽  
Satisfactory Clinical Result

Unidirectional porous β-tricalcium phosphate (UDPTCP; Affinos®, Kuraray, Tokyo, Japan) has been in clinical use since 2015. Animal studies have confirmed the excellent potential of UDPTCP with regard to bone formation and material absorption. We present the first three clinical cases using UDPTCP as a bone substitute after curettage of benign bone tumors of the hand. All three patients were males, 29-, 30- and 81-years-old, two having a diagnosis of enchondroma and the other, a bone ganglion, with a pathological fracture identified in one case. Over a mean follow-up of 10 months, all patients achieved satisfactory clinical result, with no adverse events of UDPTCP noted. Radiographic evidence of good bone formation and material absorption was observable over the postoperative course. UDPTCP provided satisfactory clinical results, with good biocompatibility and fast resorption characteristics. Therefore, UDPTCP could provide a safe and reliable filling substitute for bone defects following curettage of small bone tumors.

Sign in / Sign up

Export Citation Format

Share Document